Celularity Inc. (NASDAQ: CELU) stock jumped 2.40% on Wednesday to $2.56 against a previous-day closing price of $2.50. With 1.15 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.75 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.5800 whereas the lowest price it dropped to was $2.4500. The 52-week range on CELU shows that it touched its highest point at $13.19 and its lowest point at $1.95 during that stretch. It currently has a 1-year price target of $10.83.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CELU was down-trending over the past week, with a drop of -1.92%, but this was down by -10.49% over a month. Three-month performance dropped to -8.90% while six-month performance fell -68.55%. The stock lost -63.27% in the past year, while it has lost -50.00% so far this year. A look at the trailing 12-month EPS for CELU yields 0.20 with Next year EPS estimates of -1.05. For the next quarter, that number is -0.26. This implies an EPS growth rate of -392.60% for this year and -28.00% for next year.
Float and Shares Shorts:
At present, 140.15 million CELU shares are outstanding with a float of 40.92 million shares on hand for trading. On Jul 14, 2022, short shares totaled 3.03 million, which was 2.13% higher than short shares on Jun 14, 2022. In addition to Dr. Robert Joseph Hariri M.D., Ph.D. as the firm’s Founder, CEO & Chairman, Dr. Andrew L. Pecora CPE, F.A.C.P., FACP, M.D. serves as its Pres & Member of Scientific Advisory Board.
Through their ownership of 20.31% of CELU’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 40.41% of CELU, in contrast to 2.09% held by mutual funds. Shares owned by individuals account for 19.04%. As the largest shareholder in CELU with 10.73% of the stake, Starr Investment Holdings LLC holds 15,281,389 shares worth 15,281,389. A second-largest stockholder of CELU, C.V. Starr & Co., Inc., holds 7,640,693 shares, controlling over 5.37% of the firm’s shares. Armistice Capital LLC is the third largest shareholder in CELU, holding 1,868,128 shares or 1.31% stake. With a 1.14% stake in CELU, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 1,625,100 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 0.24% of CELU stock, is the second-largest Mutual Fund holder. It holds 346,553 shares valued at 0.94 million. Loncar Cancer Immunotherapy ETF holds 0.11% of the stake in CELU, owning 159,964 shares worth 0.43 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CELU since 6 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CELU analysts setting a high price target of $16.00 and a low target of $5.00, the average target price over the next 12 months is $10.83. Based on these targets, CELU could surge 525.0% to reach the target high and rise by 95.31% to reach the target low. Reaching the average price target will result in a growth of 323.05% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. CELU will report FY 2022 earnings on 03/30/2023. Analysts have provided yearly estimates in a range of -$0.61 being high and -$1.20 being low. For CELU, this leads to a yearly average estimate of -$0.82. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Celularity Inc. surprised analysts by $0.58 when it reported $0.32 EPS against a consensus estimate of -$0.26. The surprise factor in the prior quarter was -$0.25. Based on analyst estimates, the high estimate for the next quarter is -$0.18 and the low estimate is -$0.34. The average estimate for the next quarter is thus -$0.26.
Summary of Insider Activity:
Insiders traded CELU stock several times over the past three months with 12 Buys and 0 Sells. In these transactions, 435,137 shares were bought while 0 shares were sold. The number of buy transactions has increased to 21 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 7,498,998 while 0 shares were sold.